VANCOUVER, BC, May 16, 2022 /CNW/ – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce a partnership (the “Partnership”) with TheraPsil – a non-profit coalition made up of healthcare professionals, patients, community members, and advocates dedicated to helping Canadians in medical need access legal psilocybin-assisted psychotherapy and GMP-quality psilocybin. Under the Partnership, TheraPsil will support prescribing healthcare professionals in requesting psilocybin from HAVN Life, and other licensed dealers enrolled in TheraPsil’s “Project Solace”, through the Special Access Program (“SAP”).
